SEATTLE–(BUSINESS WIRE)–#GMPGradePlasmidDNA–According to Coherent Market Insights, the global plasmid DNA
manufacturing market was valued at US$ 65.1million in 2017, and is
projected to exhibit a CAGR of 23.7% over the forecast period (2018 –
2026).
Key Trends and Analysis of the Plasmid DNA Manufacturing Market:
Key players in the market are focused on adopting strategies such as
mergers and acquisitions to enhance their product portfolio. For
instance, in February 2016, Agilis Biotherapeutics, LLC (Agilis) and
Waisman Biomanufacturing entered into an exclusive partnership agreement
for the production of Agilis’ novel gene therapy product, AGIL-FA, for
treatment of Friedreich’s ataxia (FA).
Request Sample Copy of this Report @ https://www.coherentmarketinsights.com/insight/request-sample/2593
Europe region is expected to witness significant growth in the plasmid
DNA manufacturing market due to adoption of strategies such as
collaborations by market players. For instance, in May 2018,
PlasmidFactory GmbH & Co. KG collaborated with Sirion-Biotech GmbH,
Vibalogics GmbH, and PROGEN, for manufacturing adeno-associated virus
(AAV) vector. This collaboration was done in order to create easy
workflow from plasmid manufacturing to GMP production, and analytics of
recombinant AAV to fulfil the AAV vector demands of customers.
Moreover, an increase in the number of viral vector manufacturing
facilities to cater to requirements of GMP grade vectors for clinical
trials, is expected to propel the market growth. For instance, in 2018,
LakePharma, Inc., as U.S. based Biologics Company, inaugurated a cGMP
microBiomanufacturing Center for commercial manufacturing of non-GMP and
fully compliant GMP-grade plasmid DNA.
To know the latest trends and insights prevalent in this market,
click the link below:
https://www.coherentmarketinsights.com/market-insight/plasmid-dna-manufacturing-market-2593
Key Market Takeaways:
-
The plasmid DNA manufacturing market is expected to exhibit a CAGR of
23.7% during the forecast period (2018 – 2026), as a result of
increasing number of patients opting for gene therapy. For instance,
Adeno-associated (AAV2) vectors carrying the therapeutic gene (RPE65)
leads to improved vision of individuals suffering from Leber’s
Congenital Amaurosis. -
Moreover, according to data published by the Journal of Gene Medicine,
March 2018, an estimated 2,600 gene therapy clinical trials were
ongoing, completed, or have been approved in 36 countries. -
Key players in the market are focused on research & development,
expansion, and collaboration activities in order to enhance their
market share. For instance, in January 2019, Sarepta Therapeutics,
Inc. and Aldevron announced their collaboration. This collaboration
provided Sarepta with Aldevron’s manufacturing slots and capacity for
production of GMP grade plasmid for various programs related to gene
therapy. -
Key players operating in the global plasmid DNA manufacturing market
include Cobra Biologics and Pharmaceutical Services, VGXI, Inc.,
Aldevron, Kaneka Corporation, Nature Technology Corporation,
PlasmidFactory GmbH & Co. KG, Cell and Gene Therapy Catapult, and
Waisman Biomanufacturing.
Buy this report now @ https://www.coherentmarketinsights.com/insight/buy-now/2593
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting
firm offering action-ready syndicated research reports, custom market
analysis, consulting services, and competitive analysis through various
recommendations related to emerging market trends, technologies, and
potential absolute dollar opportunity.
Contacts
Mr. Shah
Coherent Market Insights
1001 4th Ave.
#3200
Seattle,
WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com